THU0248 Patient-Oriented Decision of Early Treatment of Rheumatoid Arthritis with Combination of Triple Conventional Disease Modifying Anti-Rheumatic Drugs or Tumor Necrosis Factor Inhibitors and Methotrexate (Prospective, Open-Label Clinical Trial)

2013 ◽  
Vol 72 (Suppl 3) ◽  
pp. A249.2-A249 ◽  
Author(s):  
M. Okada ◽  
H. Matsuno ◽  
C. Abe ◽  
K. Katayama ◽  
M. Kondo ◽  
...  
Keyword(s):  
Rheumatoid Arthritis ◽  
Clinical Trial ◽  
Tumor Necrosis Factor ◽  
Early Treatment ◽  
Tumor Necrosis ◽  
Tumor Necrosis Factor Inhibitors ◽  
Open Label ◽  
Disease Modifying ◽  
Necrosis Factor

The effect of methotrexate versus other disease-modifying anti-rheumatic drugs on serum drug levels and clinical response in patients with rheumatoid arthritis treated with tumor necrosis factor inhibitors

2018 ◽  
Vol 38 (3) ◽  
pp. 949-954 ◽  
Author(s):  
Ana Martínez-Feito ◽  
Chamaida Plasencia-Rodríguez ◽  
Victoria Navarro-Compán ◽  
Borja Hernández-Breijo ◽  
María Ángeles González ◽  
...  
Keyword(s):  
Rheumatoid Arthritis ◽  
Tumor Necrosis Factor ◽  
Clinical Response ◽  
Tumor Necrosis ◽  
Tumor Necrosis Factor Inhibitors ◽  
Drug Levels ◽  
Disease Modifying ◽  
Necrosis Factor

scholarly journals Back to Basics: Prioritizing Communication as a Key Instrument in Managing Rheumatoid Arthritis

2021 ◽  
pp. jrheum.210984
Author(s):  
Paul Studenic ◽  
Helga Radner
Keyword(s):  
Rheumatoid Arthritis ◽  
Drug Therapy ◽  
Tumor Necrosis Factor ◽  
Tumor Necrosis ◽  
Tumor Necrosis Factor Inhibitors ◽  
Disease Modifying Antirheumatic Drugs ◽  
Antirheumatic Drugs ◽  
Synthetic Dmards ◽  
Disease Modifying ◽  
Necrosis Factor

Patients with rheumatoid arthritis (RA) have come to experience a tremendous increase in therapeutic options with disease-modifying antirheumatic drugs (DMARDs).1 After decades of dissatisfying drug therapy results with conventional synthetic DMARDs (csDMARDs) only, the introduction of the first tumor necrosis factor inhibitors in the late 1990s has revolutionized RA treatment.2

The Effects of Tumor Necrosis Factor Inhibitors on Cardiovascular Risk in Rheumatoid Arthritis

2012 ◽  
Vol 18 (11) ◽  
pp. 1502-1511 ◽  
Author(s):  
Mike J.L. Peters ◽  
Alper M. van Sijl ◽  
Alexandre E. Voskuyl ◽  
Naveed Sattar ◽  
Yvo M. Smulders ◽  
...  
Keyword(s):  
Rheumatoid Arthritis ◽  
Cardiovascular Risk ◽  
Tumor Necrosis Factor ◽  
Tumor Necrosis ◽  
Tumor Necrosis Factor Inhibitors ◽  
Necrosis Factor
Sign in / Sign up

Export Citation Format

Share Document